Skip to main content
Figure 3 | BMC Medical Genetics

Figure 3

From: Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study

Figure 3

A model of genotypic effects on ketone body metabolism in mild-to-moderate Alzheimer's disease. Non-carriers of the APOE4 allele may have decreased insulin signaling allowing for increased ketone body metabolism. Carriers of the T allele of rs2251101 have elevated Ide activity relative to C carriers and therefore reduced insulin signaling. Carriers of the rs1143627 T and rs16944 C alleles have a reduced inflammatory response relative to rs1143627 C and rs16944 T carriers. This reduced inflammatory response may allow for improved ketone body metabolism. Each of the polymorphisms that reduce insulin signaling may allow for better response to induced ketosis in AD.

Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us